ArticleCureus2025
Successful Treatment of Hailey-Hailey Disease With Dupilumab.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Bimekizumab as an Effective Treatment in Darier Disease: Clinical Outcomes of a Single-Center Retrospective Analysis of Patients Treated with Biologics.Dermatology and therapy · 2026Article
- Short-term disease control with alternate-day maintenance upadacitinib in refractory Hailey-Hailey disease: a case report.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hailey-Hailey disease (HHD) is a rare autosomal dominant genodermatosis caused by mutations in the ATP2C1 gene, leading to impaired calcium homeostasis and epidermal acantholysis. Clinically, it manifests as recurrent, painful erosions in the intertriginous areas and is often resistant to conventional treatments, such as topical corticosteroids, antibiotics, and retinoids. This report describes the case of a 67-year-old woman with refractory HHD who presented with painful, pruritic erosions affecting the axillary, inguinal, and inframammary regions. Despite prior treatment with high-potency topical corticosteroids and oral retinoids, her symptoms persisted. Given the chronic and relapsing nature of HHD, dupilumab, an IL-4/IL-13 inhibitor, was initiated. The patient experienced significant symptomatic improvement within two months of therapy. This case contributes to the growing body of evidence supporting dupilumab as a potential therapeutic option for HHD and highlights the need for further research to evaluate its long-term efficacy and safety in managing this condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.